Page last updated: 2024-12-08

plasminogen activator inhibitor 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-butyrylhomoserine lactone: quorum sensing compound biosynthesized by LasI protein; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443433
CHEBI ID179573
SCHEMBL ID787006
MeSH IDM0026410

Synonyms (24)

Synonym
n-(2-oxooxolan-3-yl)butanamide
CHEBI:179573
LMFA08030002
n-butanoyl-lhomoserine lactone
n-butyrylhomoserine lactone
E048768E-5BA0-47F4-984F-2DECF94BC9B5
homoserine lactone, n-butanoyl-
SCHEMBL787006
VFFNZZXXTGXBOG-UHFFFAOYSA-N
n-butyryl-dl-homoserine lactone
n-butanoyl-dl-homoserine lactone
mfcd01862909
98426-48-3
n-butyryl-dl-homoserine lactone, >=97.0% (hplc)
HY-113764
pai-2
n-(2-oxotetrahydrofuran-3-yl)butyramide
(rac)-c4-hsl
c4-homoserine lactone
CS-0063260
F82251
MS-22929
butanamide, n-(tetrahydro-2-oxo-3-furanyl)-
AKOS040740855

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In parallel, the gacA gene dosage markedly influenced the BHL/RhIR-dependent formation of the cytotoxic compounds pyocyanin and cyanide and the exoenzyme lipase."( The global activator GacA of Pseudomonas aeruginosa PAO positively controls the production of the autoinducer N-butyryl-homoserine lactone and the formation of the virulence factors pyocyanin, cyanide, and lipase.
Beyeler, M; Foglino, M; Haas, D; Latifi, A; Lazdunski, A; Reimmann, C; Winteler, H, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acyl-amino acidA carboxamide resulting from the formal condensation of a carboxylic acid with the amino group of an amino acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (106)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (11.32)18.2507
2000's42 (39.62)29.6817
2010's41 (38.68)24.3611
2020's11 (10.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.64 (24.57)
Research Supply Index4.68 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index65.98 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.94%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other105 (99.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]